Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16886235 | 0.90 | ACHE (0.34) | — | |
| SCHEMBL20002737 | 0.81 | SLC22A12 (0.33) | SLC22A12CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL20002806 | 0.76 | SLC22A12 (0.32) | SLC22A12CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL16886243 | 0.76 | SMN1; SMN2 (0.44) | — | |
| SCHEMBL16886261 | 0.74 | KDM1A (0.38) | — | |
| SCHEMBL16886241 | 0.74 | TSHR (0.41) | CYP2D6 | |
| SCHEMBL16886258 | 0.73 | RORC (0.35) | — | |
| SCHEMBL20002774 | 0.72 | ACHE (0.36) | — | |
| SCHEMBL16886250 | 0.72 | RORC (0.36) | — | |
| SCHEMBL16886269 | 0.71 | ALB (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160326108-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2016-11-10 | — | — | US | disclosed |
| US-9458171-B2 | Pyrrolidinyl sulfone RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-04 | — | — | US | disclosed |
| US-20150191483-A1 | PYRROLIDINYL SULFONE RORGAMMA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2015-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326108-A1 | PYRROLIDINYL SULFONE DERIVATIVES AND THEIR USE AS ROR GAMMA MODULATORS | RORC, RORB, RORA | SLC22A12 2494/4885CYP1A2 398/4885CYP3A4 387/4885 |
| US-20150191483-A1 | PYRROLIDINYL SULFONE RORGAMMA MODULATORS | RORC, RORB, RORA | SLC22A12 2258/4885CYP1A2 430/4885CYP3A4 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.